From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A
The treatment of hemophilia A has progressed amazingly in recent years. Emicizumab, a bispecific-humanized monoclonal antibody, is able to improve coagulation by bridging activated factor IX and factor X. Emicizumab is administered subcutaneously and much less often compared to factor VIII products....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Palacký University Olomouc, Faculty of Medicine and Dentistry
2023-03-01
|
| Series: | Biomedical Papers |
| Subjects: | |
| Online Access: | https://biomed.papers.upol.cz/artkey/bio-202301-0001_from-a-bispecific-monoclonal-antibody-to-gene-therapy-a-new-era-in-the-treatment-of-hemophilia-a.php |